Factor VIII Variant Composition for Dual Inactivation Resistance

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for hemophilia A, primarily involving FVIII replacement therapy, are costly and only 20% of patients receive regular treatment due to the high cost, highlighting the need for FVIII molecules with improved biological properties to enhance hemostasis.

Innovation Solution

Development of Factor VIII variants, such as FVIII-QQVV (R336Q/R562Q/D519V/E665V), which are resistant to both A2-domain dissociation and activated protein C (APC) cleavage, thereby enhancing hemostatic function.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If wild-type FVIII is used for hemophilia A treatment, then the treatment is available and can be administered, but the cost is high and only 20% of patients receive regular treatment

Engineering Contradiction:

Improvehemostatic functionVSAvoidproduction cost

Core Design Contradiction:

ReliabilityVSEase of manufacture

Solution Approach 1:

The patent modifies specific amino acid parameters at positions 336, 562, 519, and 665 in the FVIII molecule to create variants with enhanced stability and resistance to degradation mechanisms, thereby improving hemostatic function without changing the fundamental production process

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The invention creates composite FVIII variants by combining multiple functional domains (A1, A2, A3, C1, C2) with specific mutations that confer both APC resistance and enhanced A2-domain stability, achieving superior hemostatic properties through integrated structural modifications

Inventive Principle:

Principle #40Composite materials

2Reliability

If FVIII replacement therapy is provided, then hemophilia A can be treated, but the high cost limits accessibility to only 20% of patients

Engineering Contradiction:

Improveclot formationVSAvoidpatient coverage

Core Design Contradiction:

ReliabilityVSQuantity of substance

Solution Approach 1:

By modifying amino acid parameters at critical positions (336, 562, 519, 665), the FVIII variants achieve enhanced stability and prolonged half-life, improving clot formation reliability which could potentially reduce treatment frequency and cost

Inventive Principle:

Principle #35Parameter changes

3Productivity

If wild-type FVIIIa is used, then coagulation function is provided, but rapid A2-domain dissociation causes inactivation within minutes

Engineering Contradiction:

Improvecoagulation activityVSAvoidhalf-life

Core Design Contradiction:

ProductivityVSDuration of action of stationary object

Solution Approach 1:

The patent introduces specific amino acid changes at positions 519 and 665 that strengthen the A2-domain interactions, directly addressing the rapid dissociation issue and extending the functional half-life of FVIIIa while maintaining high coagulation activity

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The mutations at positions 336 and 562 preemptively prevent APC-mediated cleavage, while the mutations at 519 and 665 preemptively stabilize the A2-domain structure, thereby preventing both major inactivation mechanisms before they occur

Inventive Principle:

Principle #9Preliminary anti-action

4Power

If FVIIIa is activated by thrombin, then coagulation function is enhanced, but rapid inactivation occurs due to A2-domain dissociation

Engineering Contradiction:

Improvecoagulation functionVSAvoidactivity duration

Core Design Contradiction:

PowerVSDuration of action of moving object

Solution Approach 1:

The patent modifies amino acid parameters at critical interaction sites (519, 665) to strengthen the A2-domain heterodimer stability, thereby extending the duration of coagulation activity while maintaining the enhanced power provided by thrombin activation

Inventive Principle:

Principle #35Parameter changes

Data Source

PatentUS20250250322A1Compositions and methods for modulating factor viii function

Publication Date: 2025.08.07 THE CHILDRENS HOSPITAL OF PHILADELPHIA

AI summary

Factor VIII variants and methods of use thereof are disclosed.